The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Seth A. Wander, MD, PhD, Reshma L. Mahtani, DO, and Shanu Modi, MD, review pivotal data regarding the use of antibody-drug conjugates in the treatment of metastatic triple-negative breast cancer, and discuss how they apply these data in the management of their patients.

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Faculty:

Reshma L. Mahtani, DO

Medical Oncologist
Chief, Breast Medical Oncology
Baptist Health Miami Cancer Institute
Miami, FL

Disclosures: Consultant: Agendia, Arvinas, AstraZeneca, Daiichi Sankyo, Eisai, Genentech, Hologic, Lilly, Novartis, Pfizer, Sermonix, Stemline; Grant/Research Support: Gilead Sciences

Shanu Modi, MD

Breast Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca, Ataraxis, Bayer, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, D3 Bio, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, GSK, MacroGenics, Nuvation Bio, Pfizer, Seattle Genetics; Grant/Research Funding: ALX Oncology, AstraZeneca, BioNTech, BriaCell, D3 Bio, Daiichi Sankyo, DualityBio, Genentech, Nuvation Bio, Pfizer, Seattle Genetics

Seth A. Wander, MD, PhD

Assistant Professor of Medicine
Harvard Medical School
Medical Oncologist
Massachusetts General Hospital
Boston, MA

Disclosures: Advisor, Consultant, Fee for Service Recipient: Arvinas, AstraZeneca, Biovica, Boundless Bio, Celcuity, Delcath, Eli Lilly, Foundation Medicine, Genentech, Gilead, Halda Therapeutics, Hologic, Novartis, Pfizer, Puma Biotechnology, Regor Therapeutics, Stemline/Menarini, Veracyte; Grant/Research Funding: Arvinas, Eli Lilly, Genentech, Nuvation Bio, Pfizer, Phoenix Molecular Designs, Puma Biotechnology, Regor Therapeutics, Sermonix, Stemline/Menarini

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on antibody-drug conjugates in the treatment of hormone receptor-positive/HER2-negative, as well as HER2-positive, metastatic breast cancers, go to https://www.gotoper.com/ibc26adcs-activity.

Release Date

September 11, 2026

Expiration Date

September 11, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this activity is for education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.